{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:34:44Z","timestamp":1792103684773,"version":"4.4.0"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Advanced chronic kidney disease (CKD) presents a complex hemostatic paradox, characterized by a simultaneous increase in bleeding and thromboembolic risks. This study aimed to evaluate and compare the safety and efficacy of apixaban versus acenocoumarol in a real-world cohort of patients across advanced CKD stages (pre-dialysis and hemodialysis). We conducted a retrospective observational study including 84 adults with CKD stages 4 and 5 (40.5% in stage 4; 59.5% in stage 5, of whom 86.0% were on chronic hemodialysis) receiving oral anticoagulation for at least 3 months. Patients were stratified by CKD stage and anticoagulant type (apixaban vs. acenocoumarol). Clinical outcomes included major and clinically relevant bleeding, anticoagulant overdose, and thromboembolic events. Bleeding events were more frequent in CKD stage 5 than in stage 4 (66.0% vs. 44.1%, p = 0.06), highlighting a pronounced hemorrhagic burden that increases with disease progression. Apixaban was associated with significantly fewer total bleeding events (44.4% vs. 66.7%, p = 0.04) and a lower rate of anticoagulant overdoses (5.6% vs. 18.8%, p = 0.04) compared with acenocoumarol. Thromboembolic event rates did not differ significantly between the two anticoagulant groups (13.9% vs. 16.7%, p = 0.72). Conventional risk scores (CHA2DS2-VASc and HAS-BLED) showed limited discriminatory capacity for actual clinical events in this advanced CKD population. In patients with advanced CKD, oral anticoagulation is associated with a high hemorrhagic burden that intensifies as renal function declines. Apixaban demonstrated a more favorable safety profile than acenocoumarol without a loss of thromboembolic protection. These findings suggest that stage-specific biological factors, rather than conventional risk models alone, should guide anticoagulation strategies in this population.<\/jats:p>","DOI":"10.3390\/ijms27062577","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:43:18Z","timestamp":1773240198000},"page":"2577","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anticoagulation Therapy in Advanced Chronic Kidney Disease: Balancing Bleeding and Thromboembolic Risk"],"prefix":"10.3390","volume":"27","author":[{"given":"Ioana Livia","family":"Suliman","sequence":"first","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-1287","authenticated-orcid":false,"given":"Liliana-Ana","family":"Tuta","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Pana","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin Gabriel","family":"Panculescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1420-1034","authenticated-orcid":false,"given":"Andreea","family":"Alexandru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Fasie","sequence":"additional","affiliation":[{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Cimpineanu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stere","family":"Popescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7922-647X","authenticated-orcid":false,"given":"Florin-Daniel","family":"Enache","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu Adrian","family":"Nitu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4996-2484","authenticated-orcid":false,"given":"Tatiana","family":"Chisnoiu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7114-5226","authenticated-orcid":false,"given":"Marius Florentin","family":"Popa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana-Cezara","family":"Tudor","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9660-0848","authenticated-orcid":false,"given":"Mihaela Lavinia","family":"Mihai","sequence":"additional","affiliation":[{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5113-0149","authenticated-orcid":false,"given":"Sorin","family":"Deacu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"\u201dSfantul Apostol Andrei\u201d Emergency County Clinical Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-5933","authenticated-orcid":false,"given":"Georgeta Camelia","family":"Cozaru","sequence":"additional","affiliation":[{"name":"Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology (CEDMOG), \u201cOvidius\u201d University of Constanta, 900591 Constanta, Romania"},{"name":"Academy of Romanian Scientist, 3 Ilfov Street, 050044 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion","family":"Bordeianu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Parul, F., Ratnani, T., Subramani, S., Bhatia, H., Ashmawy, R.E., Nair, N., Manchanda, K., Anyagwa, O.E., Kaka, N., and Patel, N. (2025). Anticoagulation in Patients with End-Stage Renal Disease: A Critical Review. Healthcare, 13.","DOI":"10.3390\/healthcare13121373"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes Associated with Apixaban Use in Patients with End-Stage Kidney Disease and Atrial Fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tuta, L., Stanigut, A., Campineanu, B., and Pana, C. (2018). Novel Oral Anticoagulants in Patients with Severe Chronic Kidney Disease, a Real Challenge. Nephrology Dialysis Transplantation, Oxford University Press.","DOI":"10.1093\/ndt\/gfy104.SP305"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban Versus Warfarin in Patients with Atrial Fibrillation and Advanced Chronic Kidney Disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e240163","DOI":"10.57264\/cer-2024-0163","article-title":"US cost-effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total","volume":"14","author":"Atreja","year":"2025","journal-title":"J. Comp. Eff. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week","volume":"74","author":"Kumar","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Vio, R., Proietti, R., Rigato, M., and Cal\u00f2, L.A. (2021). Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030279"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Suliman, I.L., Panculescu, F.G., Cimpineanu, B., Popescu, S., Fasie, D., Cozaru, G.C., Gafar, N., Tuta, L.-A., and Alexandru, A. (2025). The Interplay of Cardiovascular Comorbidities and Anticoagulation Therapy in ESRD Patients on Haemodialysis\u2014The South-Eastern Romanian Experience. Biomedicines, 13.","DOI":"10.3390\/biomedicines13102387"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kister, T.S., Remmler, J., Schmidt, M., Federbusch, M., Eckelt, F., Isermann, B., Richter, H., Wehner, M., Krause, U., and Halbritter, J. (2021). Acute kidney injury and its progression in hospitalized patients-Results from a retrospective multicentre cohort study with a digital decision support system. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0254608"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/10600280221129831","article-title":"The Risk of Major Bleeding with Apixaban Administration in Patients with Acute Kidney Injury","volume":"57","author":"Givens","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcrc.2020.05.003","article-title":"Risk of incident bleeding after acute kidney injury: A retrospective cohort study","volume":"59","author":"Zarka","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lin, Y.S., Lin, M.S., Wu, V.C., Chen, Y.L., Chang, J.J., Chu, P.H., Lip, G.Y.H., and Chen, M.C. (2021). Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.775564"},{"key":"ref_16","first-page":"649","article-title":"AF and Venous Thromboembolism\u2014Pathophysiology, Risk Assessment and CHADS-VASc score","volume":"5","author":"Shariff","year":"2012","journal-title":"J. Atr. Fibrillation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10760296211021158","DOI":"10.1177\/10760296211021158","article-title":"Critical Analysis of Apixaban Dose Adjustment Criteria","volume":"27","author":"Vu","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_18","unstructured":"Bristol-Myers Squibb Company (2021). Eliquis (Apixaban) [Package Insert], Bristol-Myers Squibb Company."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A Randomized Controlled Trial Comparing Apixaban with the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC): Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_22","unstructured":"KDIGO Work Group (2022). KDIGO clinical practice guideline for CKD management. Kidney Int. Suppl., 102, S1\u2013S150."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and Cystatin C\u2013Based Equations to Estimate GFR without Race","volume":"385","author":"Inker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jhm.12926","article-title":"Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study","volume":"17","author":"Ellenbogen","year":"2022","journal-title":"J. Hosp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1055\/s-0041-1740254","article-title":"Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease","volume":"122","author":"Cohen","year":"2022","journal-title":"Thromb. Haemost."},{"key":"ref_28","first-page":"179","article-title":"A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban","volume":"6","author":"Frost","year":"2014","journal-title":"Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:44:20Z","timestamp":1773240260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27062577"],"URL":"https:\/\/doi.org\/10.3390\/ijms27062577","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}